公告提到，本次收购事项不构成关联交易，不构成《上市公司重大资产重组管理办法》规定的重大资产 重组。 2025年12月10日，广州医药以5.05亿元的价格成功摘牌，并向台州市产权交易所有限公司缴纳竞买保证 金8600万元。2025年12月17日，广州医药与海正药业签署《股权交易合同》及《补充协议》，以其自有 资金收购海正药业持有的目标公司100%股权，目标股权转让价款为50,050.00万元。 近日，广州白云山（600332）发布公告称，为进一步优化广州医药在华东区域的产业布局，推动广州医 药业务发展，经本公司董事会战略发展与投资委员会2025年第十次会议审议，同意广州医药通过公开摘 牌的方式参与海正药业（600267）转让其持有的全资子公司浙江医工100%股权事宜。 ...

Group 1 - Comcast has proposed a merger of its NBCUniversal business with Warner Bros. Discovery, valuing the combined entity at $81 billion [1] - The merger proposal includes a valuation of Warner Bros. Discovery's streaming and film assets at $35.43 per share, consisting of $5.25 in cash and 49% equity in the new entity for Warner Bros. Discovery shareholders [1] - Comcast believes that merging its entertainment assets with those of Warner Bros. Discovery will create a more valuable entity than operating independently, with Comcast holding 51% of the new business [1] Group 2 - The proposal does not include certain cable networks such as USA, CNBC, and MS Now, which are set to be spun off to shareholders as Versant Media Group [2] - Comcast's acquisition plan focuses on integrating NBCUniversal's media, theme parks, and film production businesses with Warner Bros. Discovery's film studios and streaming divisions [2] - Comcast's cash offer is considered relatively low compared to other proposals, but it offers a significant equity stake in the merged entertainment company [2]

PresentationIt's now my pleasure to turn the call over to John Fraunces, Director, Corporate Communications for LifeSci Advisors. Please go ahead, John.Good morning, and welcome to the VYNE Therapeutics conference call to discuss the merger of VYNE and Yarrow Bioscience. This call is being recorded for replay at the company's request.John FrauncesLifesci Advisors, LLC Good morning, and thank you for joining us for today's conference call. The link to this webcast is on the Investors page of the VYNE Therape ...

Core Viewpoint - Paramount is firmly supporting its proposal to acquire Warner Bros. Discovery (WBD), cautioning shareholders against accepting Netflix's offer, which it claims would leave them with a "heavily indebted, sub-scale linear business" [1] Group 1: Acquisition Proposals - Paramount made a hostile bid to acquire WBD for $108 billion, including debt, while Netflix's offer is for nearly $83 billion, focusing only on the Warner studio and streaming division [2] - Paramount is willing to take on the troubled cable network side of WBD, which has been a significant point of contention in the valuation of the bids [3] Group 2: Financial Assurance and Strategy - Paramount asserts that its bid offers "100% cash" with no exposure to equity market fluctuations, contrasting with Netflix's proposal that includes stock, which has already seen a decline [4] - The financing for Paramount's offer includes $41 billion in new equity backed by the Ellison family and RedBird Capital, along with $54 billion in debt commitments from major banks [4] Group 3: Competitive Positioning - Paramount claims its acquisition would enhance competition in the creative industries, opposing the notion that Netflix's deal would create a dominant streaming monopoly [4] - The company emphasizes that it has received positive feedback from WBD shareholders regarding its offer, which it believes is superior in value and certainty [4] Group 4: Market Reaction - Following the announcement, Paramount's shares fell by 5% in early trading [4]

Core Viewpoint - Warner Brothers Discovery has officially rejected Paramount's tender offer of $30 per share in cash, citing various reasons for their decision [2][5]. Group 1: Rejection of Paramount's Offer - Warner Brothers Discovery's board has stated a clear "no thank you" to Paramount's bid, emphasizing that the offer does not meet their expectations [2]. - The rejection is based on claims that Paramount has misled Warner Brothers shareholders regarding the financial backing from the Ellison family, which Warner Brothers asserts does not exist [3][4]. Group 2: Financing Concerns - Warner Brothers highlights that Paramount's proposal relies on an "unknown and opaque revocable trust" for funding, rather than a solid commitment from the Ellison family [4]. - Despite Paramount's assertions that the Ellison family could provide the necessary equity of approximately $48 billion, Warner Brothers maintains that no such commitment has been made [5]. Group 3: Competitive Review Process - Warner Brothers claims to have conducted a transparent and competitive review process, establishing a level playing field for potential bidders [5]. - In contrast, Paramount feels disadvantaged and believes that their final offer did not receive adequate consideration from Warner Brothers [6]. Group 4: Regulatory Considerations - Warner Brothers does not believe there is a significant regulatory risk difference between Paramount and Netflix, countering the perception that Paramount would face a smoother regulatory review process [6][7]. - The ongoing situation raises questions about whether Paramount will increase its offer to trigger Netflix's matching rights under its merger agreement with Warner Brothers [7].

Group 1 - CICC is planning to absorb and merge Dongxing Securities and Xinda Securities through a share swap, with trading resuming on December 18, 2025 [1] - Victory Energy's major shareholder plans to transfer 29.99% of its shares to Qiteng Robotics, with no plans for asset restructuring in the next 12 months [2] - China Metallurgical Group intends to repurchase A-shares worth 1 to 2 billion yuan at a price not exceeding 4.9 yuan per share [3] Group 2 - Boten Co. plans to acquire part of the Yifeng Yunding Fund for 1 yuan, with a commitment to fulfill a 20 million yuan capital contribution [4] - Tongyou Technology has initiated a 50 million yuan accounts receivable factoring business [5] - Gaode Infrared has received approval to issue debt financing tools totaling up to 3 billion yuan [6] Group 3 - Zhengyu Industrial's application for a private placement of A-shares has been approved by the Shanghai Stock Exchange [7] - China CRRC signed contracts totaling approximately 53.31 billion yuan, accounting for 21.6% of its projected 2024 revenue [9] - High Energy Environment's director increased his stake by purchasing 56,100 shares [10] Group 4 - Shantou Technology received approval from the CSRC for a convertible bond issuance [11] - Puyang Co. plans to use up to 900 million yuan of idle funds for entrusted wealth management [12] - Huibai New Materials has been awarded a government subsidy of 3.8 million yuan, with the first installment of 2.12 million yuan already received [13] Group 5 - Jiayuan Technology's shareholders plan to transfer 2.51% of the company's shares through a pricing inquiry [14] - Lingpai Technology's subsidiary terminated a 125 million yuan procurement contract due to market changes [15] - Juguang Technology intends to use up to 200 million yuan of idle funds for cash management [16] Group 6 - Zhongwen Media's subsidiary terminated a 200 million yuan private equity fund subscription due to market changes [17] - Zhifei Biological's modified vaccine for monkeypox has received clinical trial acceptance [19] - GeKowei's subsidiary received a government subsidy of 60 million yuan, accounting for 32.12% of the company's audited net profit [20] Group 7 - Wantai Biological's application for a clinical trial of a respiratory syncytial virus vaccine has been accepted [21] - Haitai Technology plans to increase capital in its Thai joint venture from 500,000 to 3 million Thai baht [22] - Shanghai Airport signed contracts for the transfer of duty-free store operating rights [23] Group 8 - Del Shares received approval to issue shares for the acquisition of 100% of Aizhuo Intelligent [24] - Novozymes' products have obtained EU CE IVDR certification [25] - Shibai Testing's chairman's assistant plans to increase shareholding by 8 to 12 million yuan [26] Group 9 - Huitian New Materials plans to invest approximately 97.68 million yuan in a lithium battery anode glue project [27] - Pudong Construction's subsidiaries won contracts totaling 1.649 billion yuan [29] - Acolyte's subsidiary has entered trial production for a special high-temperature resistant resin project [30] Group 10 - Pingzhi Information's subsidiary signed a 38.25 million yuan computing power service contract [31] - Tianma Technology is required to pay 5.3625 million yuan in taxes and penalties [32] - Yahon Pharmaceutical's clinical trial application for GLX002 has been approved [34]

通业科技公告，公司拟以现金方式购买北京思凌科半导体技术有限公司100%的股权，资金来源为自有 及自筹资金。若本次交易能够顺利实施完成，公司将持有思凌科100%的股权，思凌科将成为公司的全 资子公司。本次交易可能构成《上市公司重大资产重组管理办法》规定的重大资产重组。本次交易不涉 及公司发行股份，也不会导致公司控股股东和实际控制人发生变更。 ...

奈飞（NFLX）与派拉蒙天空之舞（PSKY）正竞相收购华纳兄弟探索公司（WBD），此举引发关注。 分析师指出，派拉蒙天空之舞集团过往多次并购均陷入困境，投资者因此对溢价过高和整合风险保持谨 慎。 责任编辑：张俊 SF065 奈飞（NFLX）与派拉蒙天空之舞（PSKY）正竞相收购华纳兄弟探索公司（WBD），此举引发关注。 分析师指出，派拉蒙天空之舞集团过往多次并购均陷入困境，投资者因此对溢价过高和整合风险保持谨 慎。 责任编辑：张俊 SF065 ...

东杰智能（300486）(300486.SZ)公告，公司正在筹划发行股份及支付现金购买山东齐康智合创业投资 管理有限公司等交易对方合计持有的遨博(北京)智能科技股份有限公司(简称"遨博智能")控股权并配套 募集资金。公司证券自2025年12月17日开市时起开始停牌。 ...

飞亚达（000026.SZ）12月16日在投资者互动平台表示，您好，感谢您对飞亚达公司的关注！公司收购 长空齿轮控股权相关工作仍在推进中，交易方案尚未最终确定，存在不确定性，请您关注公司后续公告 及注意投资风险。谢谢！ 每经AI快讯，有投资者在投资者互动平台提问：在推进并购一事上，公司为何到目前都没有最新进 展？ （文章来源：每日经济新闻） ...